Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
$1.73
+1.2%
$1.69
$0.77
$14.00
$7.02M1.485.06 million shs139,362 shs
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
$0.20
+1.2%
$0.18
$0.06
$0.22
$82.39M0.67289,478 shs251,000 shs
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
$2.20
$2.20
$0.56
$8.60
$15.98M2.33932,542 shs282,689 shs
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$6.54
-6.0%
$10.50
$0.29
$3.72
$277.75M3.931.22 million shs1.78 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
+0.59%-26.29%+26.67%+37.90%-80.84%
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
-0.41%+2.11%-3.00%+85.11%+38.57%
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-6.03%+0.15%+2.35%+47.63%-39.39%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
0.2002 of 5 stars
0.02.00.00.02.60.80.6
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/A
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
N/AN/AN/AN/A
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
N/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/A$2.46 per shareN/A
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
$560K147.12N/AN/A($0.02) per share-9.82
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
$7.38M2.17N/AN/A$6.68 per share0.33
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
$22.50M12.34N/AN/A$1.04 per share6.29

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$5.12M-$5.72N/AN/AN/AN/A-250.52%-183.24%5/10/2024 (Estimated)
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
-$3.10MN/A0.00N/A-555.91%N/A-189.49%5/10/2024 (Estimated)
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
-$70.08M-$22.85N/AN/AN/A-798.18%-210.86%-121.73%N/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/AN/A
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
N/AN/AN/AN/AN/A
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/A
4.90
4.90
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
N/A
0.15
0.15
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
0.06
3.66
3.56
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
0.18
2.90
2.90

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
44.06 million3.47 millionNo Data
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
4419.50 million369.16 millionNot Optionable
Tetraphase Pharmaceuticals Inc stock logo
TTPH
Tetraphase Pharmaceuticals
1197.26 millionN/AOptionable
Cogent Biosciences, Inc. stock logo
UMRX
Cogent Biosciences
7242.47 millionN/ANot Optionable

UMRX, ADIL, TTPH, and PVCT Headlines

SourceHeadline
Cogent Biosciences IncCogent Biosciences Inc
money.usnews.com - April 24 at 4:34 AM
Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)
markets.businessinsider.com - February 26 at 5:33 PM
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)
markets.businessinsider.com - February 26 at 8:53 AM
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
markets.businessinsider.com - February 26 at 8:53 AM
Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside PotentialBuy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential
markets.businessinsider.com - February 15 at 8:43 AM
Cogent Biosciences Stock Soars After $225M Private PlacementCogent Biosciences Stock Soars After $225M Private Placement
marketwatch.com - February 14 at 10:02 AM
Cogent Biosciences announces oversubscribed $225M private placementCogent Biosciences announces oversubscribed $225M private placement
msn.com - February 14 at 10:02 AM
Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug ProspectsBuy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects
markets.businessinsider.com - February 9 at 2:23 AM
Citi starts Cogent Biosciences at buy, cites GI tumor drug potentialCiti starts Cogent Biosciences at buy, cites GI tumor drug potential
msn.com - February 8 at 4:22 PM
Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT TrialBuy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial
markets.businessinsider.com - December 15 at 7:55 PM
Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for BezuclastinibMaintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib
markets.businessinsider.com - December 13 at 5:33 PM
Dow Surges 100 Points; Cogent Biosciences Shares PlungeDow Surges 100 Points; Cogent Biosciences Shares Plunge
markets.businessinsider.com - December 11 at 12:21 PM
Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis TreatmentCogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment
markets.businessinsider.com - December 11 at 12:21 PM
Cogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic MastocytosisCogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosis
markets.businessinsider.com - December 11 at 10:08 AM
Cogent slumps after mid-stage data for rare disorder therapyCogent slumps after mid-stage data for rare disorder therapy
msn.com - December 11 at 10:08 AM
Potential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced SharesPotential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Shares
markets.businessinsider.com - November 21 at 9:11 AM
Promising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent BiosciencesPromising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciences
markets.businessinsider.com - November 14 at 8:40 AM
Promising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent BiosciencesPromising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciences
markets.businessinsider.com - November 4 at 5:21 PM
Promising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy RatingPromising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Rating
markets.businessinsider.com - October 28 at 7:55 AM
Analyst Expectations for Cogent Biosciencess FutureAnalyst Expectations for Cogent Biosciences's Future
benzinga.com - August 30 at 8:53 AM
Cogent Biosciences Is Beginning To Differentiate Its KIT InhibitorCogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor
msn.com - August 15 at 5:40 PM
LifeSci Capital Remains a Buy on Cogent Biosciences (COGT)LifeSci Capital Remains a Buy on Cogent Biosciences (COGT)
markets.businessinsider.com - August 8 at 3:59 PM
Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?
msn.com - July 11 at 1:47 PM
Cogent Biosciences Shares Rise on Fairmount Funds Managements Stake AcquisitionCogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisition
marketwatch.com - June 13 at 11:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adial Pharmaceuticals logo

Adial Pharmaceuticals

NASDAQ:ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Provectus Biopharmaceuticals logo

Provectus Biopharmaceuticals

OTCMKTS:PVCT
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections; as well as vertebrate development, wound healing, and tissue regrowth. The company has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Tetraphase Pharmaceuticals logo

Tetraphase Pharmaceuticals

NASDAQ:TTPH
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Cogent Biosciences logo

Cogent Biosciences

NASDAQ:UMRX
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.